Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Influenza

Free Subscription Articles published in Drugs Retrieve available abstracts of 33 articles: HTML format

Single Articles

September 2023
1. BLAIR HA
   Remdesivir: A Review in COVID-19.
   Drugs. 2023;83:1215-1237.
   PubMed     Abstract available
   
   
   June 2023
2. POLAK TB, Cucchi DGJ, Schelhaas J, Ahmed SS, et al
   Results from Expanded Access Programs: A Review of Academic Literature.
   Drugs. 2023;83:795-805.
   PubMed     Abstract available
   
   
   May 2023
3. CHEN TY, Wang SI, Hung YM, Hartman JJ, et al
   Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study.
   Drugs. 2023;83:621-632.
   PubMed     Abstract available
   
   
   February 2023
4. KEAM SJ
   Nirsevimab: First Approval.
   Drugs. 2023;83:181-187.
   PubMed     Abstract available
   
   
   
5. XIE J, Brash JT, Turkmen C, Driessen S, et al
   Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study.
   Drugs. 2023;83:249-263.
   PubMed     Abstract available
   
   
   January 2023
6. PLOCQUE A, Mitri C, Lefevre C, Tabary O, et al
   Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
   Drugs. 2023;83:1-36.
   PubMed     Abstract available
   
   
   August 2022
7. HOY SM
   Amubarvimab/Romlusevimab: First Approval.
   Drugs. 2022;82:1327-1331.
   PubMed     Abstract available
   
   
   July 2022
8. DHILLON S
   Desidustat: First Approval.
   Drugs. 2022;82:1207-1212.
   PubMed     Abstract available
   
   
   June 2022
9. KEAM SJ
   Tixagevimab + Cilgavimab: First Approval.
   Drugs. 2022;82:1001-1010.
   PubMed     Abstract available
   
   
   
10. KOUFAKIS T, Mustafa OG, Ajjan RA, Garcia-Moll X, et al
    From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients.
    Drugs. 2022;82:949-955.
    PubMed     Abstract available
    
    
    March 2022
11. LAMB YN
    Nirmatrelvir Plus Ritonavir: First Approval.
    Drugs. 2022 Mar 19. pii: 10.1007/s40265-022-01692.
    PubMed     Abstract available
    
    
    
12. HEO YA
    Sotrovimab: First Approval.
    Drugs. 2022;82:477-484.
    PubMed     Abstract available
    
    
    
13. SYED YY
    Molnupiravir: First Approval.
    Drugs. 2022;82:455-460.
    PubMed     Abstract available
    
    
    February 2022
14. MAZZA MG, Vai B, De Picker L, Benedetti F, et al
    Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".
    Drugs. 2022;82:349-351.
    PubMed    
    
    
    
15. LENZE EJ, Reiersen AM, Facente SN
    Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARSCoV2 Infection: A Review of Current Evidence".
    Drugs. 2022;82:353-354.
    PubMed    
    
    
    January 2022
16. RIZK JG, Wenziger C, Tran D, Hashemi L, et al
    Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
    Drugs. 2022;82:43-54.
    PubMed     Abstract available
    
    
    December 2021
17. FACENTE SN, Reiersen AM, Lenze EJ, Boulware DR, et al
    Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
    Drugs. 2021;81:2081-2089.
    PubMed     Abstract available
    
    
    
18. SYED YY
    Regdanvimab: First Approval.
    Drugs. 2021;81:2133-2137.
    PubMed     Abstract available
    
    
    November 2021
19. DEEKS ED
    Casirivimab/Imdevimab: First Approval.
    Drugs. 2021;81:2047-2055.
    PubMed     Abstract available
    
    
    September 2021
20. AHMED N, Pezacki JP
    Reply to Zhang and Zhu "MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19".
    Drugs. 2021;81:1693-1695.
    PubMed    
    
    
    
21. ZHANG S, Zhu F
    Comment on: "MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19".
    Drugs. 2021;81:1691-1692.
    PubMed    
    
    
    July 2021
22. ROE MT, Patrick-Lake B, von Eschenbach AC
    Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments.
    Drugs. 2021;81:1235-1237.
    PubMed    
    
    
    June 2021
23. VUORIO A, Kovanen PT
    Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry".
    Drugs. 2021;81:1125-1127.
    PubMed    
    
    
    April 2021
24. HEO YA
    Voclosporin: First Approval.
    Drugs. 2021;81:605-610.
    PubMed     Abstract available
    
    
    
25. HUM C, Loiselle J, Ahmed N, Shaw TA, et al
    MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.
    Drugs. 2021;81:517-531.
    PubMed     Abstract available
    
    
    
26. TORRES-PENA JD, Perez-Belmonte LM, Fuentes-Jimenez F, Lopez Carmona MD, et al
    Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry.
    Drugs. 2021;81:685-695.
    PubMed     Abstract available
    
    
    March 2021
27. LAMB YN
    BNT162b2 mRNA COVID-19 Vaccine: First Approval.
    Drugs. 2021;81:495-501.
    PubMed     Abstract available
    
    
    December 2020
28. LIN KJ, Schneeweiss S, Tesfaye H, D'Andrea E, et al
    Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity.
    Drugs. 2020;80:1961-1972.
    PubMed     Abstract available
    
    
    October 2020
29. CANTINI F, Goletti D, Petrone L, Najafi Fard S, et al
    Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
    Drugs. 2020 Oct 17. pii: 10.1007/s40265-020-01421.
    PubMed     Abstract available
    
    
    
30. HAJRA A, Mathai SV, Ball S, Bandyopadhyay D, et al
    Management of Thrombotic Complications in COVID-19: An Update.
    Drugs. 2020;80:1553-1562.
    PubMed     Abstract available
    
    
    September 2020
31. VRACHATIS DA, Giotaki SG, Giannopoulos G, Deftereos S, et al
    Comment on: "Pharmaco-Immunomodulatory Therapy in COVID-19".
    Drugs. 2020;80:1499-1500.
    PubMed    
    
    
    
32. RIZK JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, et al
    Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy I COVID-19".
    Drugs. 2020;80:1501-1503.
    PubMed    
    
    
    
33. BIANCONI V, Violi F, Fallarino F, Pignatelli P, et al
    Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?
    Drugs. 2020;80:1383-1396.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: